Source: EURLEX
Language: en
Format: md

|  |  |  |  |
| --- | --- | --- | --- |
| 20.9.2021 | EN | Official Journal of the European Union | C 382/34 |

---

Action brought on 9 August 2021 — Glaxo Group v EUIPO — Cipla Europe (Shape of an inhaler)

(Case T-477/21)

(2021/C 382/47)

Language of the case: English

Parties

Applicant: Glaxo Group Ltd (Brentford, United Kingdom) (represented by: T. de Haan and F. Verhoestraete, lawyers)

Defendant: European Union Intellectual Property Office (EUIPO)

Other party to the proceedings before the Board of Appeal: Cipla Europe NV (Antwerp, Belgium)

Details of the proceedings before EUIPO

Proprietor of the trademark at issue: Applicant before the General Court

Trade mark at issue: European Union tridimensional mark (Shape of an inhaler) — European Union trade mark No 2 179 562

Procedure before EUIPO: Cancellation proceedings

Contested decision: Decision of the First Board of Appeal of EUIPO of 19 May 2021 in Case R 1835/2016-1

Form of order sought

The applicant claims that the Court should:

|  |  |
| --- | --- |
| — | set aside the contested decision; |

|  |  |
| --- | --- |
| — | order EUIPO and the intervener to bear the costs, including those incurred by the applicant before the Office’s First Board of Appeal. |

Pleas in law

|  |  |
| --- | --- |
| — | Infringement of Articles 94(1) of Regulation (EU) 2017/1001 of the European Parliament and of the Council and 41(2) of the Charter of Fundamental Rights of the EU; |

|  |  |
| --- | --- |
| — | Infringement of Article 7(1)(b) of Council Regulation (EC) 40/94; |

|  |  |
| --- | --- |
| — | Infringement of Article 52(2) of Council Regulation (EC) 207/2009. |

---

[Top](#document1)